About Lyric Bio
We are a newly founded biotech company run by experienced founders excited about translating tissue engineering technology into next-generation biomanufacturing.
Manufacturing of therapeutics might sound boring to some, but without the biomanufacturing revolution alongside of the biotechnology revolution there would be no stable supply of life saving insulin, monoclonal antibodies, hormones, or enzymes.
Today, there are still several categories of therapeutics that are too complex to be manufactured with existing technologies. For example, Human Immunoglobulin (IvIg and ScIg), Red Blood Cells, and Stem Cells; each representing a multi-billion dollar market where the product is sourced solely through human donation. These therapeutics, that we’re calling Complex Therapeutics, due to their inability to be produced with standard manufacturing methods, suffer from inflated costs and supply shortages that limit patient access.
Lyric’s goal is to eliminate global shortages of critical medicines by enabling scalable manufacturing of Complex Therapeutics.
Using proprietary 3D printing and tissue engineering technology we are developing bioreactors that can support cell densities similar to those found in human tissues. Most of the cell types needed to produce Complex Therapies are tissue resident, meaning that they are typically found in densely packed human tissue. These cells cannot be cultured efficiently in standard bioreactors that rely on suspension cell types. Ultra high-density bioreactors will enable significantly less expensive production of proteins and provide a more physiologic environment for cell replication and development.
We’ve done the math.
Using tissue-like bioreactors our team at Lyric believes we can deliver Complex Therapeutics with significantly greater efficiency than human donation. We are looking forward to eliminating supply shortages for these life-saving medicines. Learn more about us at www.Lyricbio.com or contact us at info@lyricbio.com for more information.